Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja C Weisel

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
Nature Medicine|April 6, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trialFrancesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple MyelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
Nature Medicine|April 6, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trialFrancesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple MyelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Pageof 10